Listening for arrhythmias

Over-the-phone voice analysis detects atrial fibrillation

“The mother of one of our founders had a stroke due to A-fiband he couldn’t believe that the detection capability is so low - less than 10 percent,” says James Amihood, speaking with ISRAEL21c from the five-year-old company’s headquarters in Israel’s Airport City.

“He realized that there is an unmet need for a cost-effective way to monitor senior patients more frequently. And it must be age-friendly because older people don’t like wearables.”

Voice analysis was the answer that Cardiokol’s founders came up with (kol is Hebrew for “voice”).

Atrial Fibrillation can be detected from voice samples only!

We invite you to read a short article published lately at Healio,
where head of electrophysiology and pacing unit in the department of cardiology at Rabin Medical Center, Dr. Gregory Golovchiner is being interviewed regarding a recent study he led together with Prof. Moshe Swissa, head of electrophysiology and pacing unit in the department of cardiology at Kaplan Medical center, and Prof. Michael Glikson, Director of the Jesselson Integrated Heart Center of Shaare Zedek Medical Center in Jerusalem.

This is the first study to examine the correlation between voice features and atrial fibrillation.

As Dr. Golovchiner says, “The findings of this study open horizons for non-invasive, low-cost, age-friendly, prolonged and systematic monitoring of patients with known AF, as well as screening for AF in populations at risk.”

We've reached 500 followers on LinkedIn!

This is a great opportunity to thank you all for your support and interest in Cardiokol's mission to use our voice platform to save lives.

A very warm welcome to everyone who has joined us in recent months, and a special thanks to those who have been following us since the beginning!

Our aim is to promote awareness for afib (Atrial Fibrillation) prevention here on LinkedIn, share with you our journey in the field, and continue engaging with you.

We look forward to reaching new successful milestones!

We are proud to be selected among the six healthtech promising startups participating in the #5 cohort of Hadassah Accelerator and IBM Alpha Zone program. It’s all about accelerating Cardiokol's clinical, technological and business development.

By working closely with IBM Alpha Zone and Hadassah Accelerator, we bring the company closer to the clinicians, patients and real-world data, coupled with the best-of-breed technologies and advice of experts.

We are proud to announce our 8 finalists who were selected to participate in the Digital Health Accelerator program!

We had 100 companies apply and were so impressed with the groundbreaking technology that is being invented here in Israel. We know the next big thing in Digital Health will be from Haifa, and we are so excited to work with these 8 amazing companies to expand their ideas and change the world of healthcare.

We'd like to thank tech12, Oracle and Tal Shahaf for raising the awareness of Afib (Atrial Fibrillation) and Cardiokol voice technology for supporting the detection of Afib most common - often silent - heart arrhythmia and keystroke risk.James Amihood Cardiokol CEO said that "this age-friendliest technology has many benefits and it does not require the use of any special devices or wearables besides landline, mobile phone or digital voice assistant. It can easily be operated on a large scale, for example in call centers and telecom clouds to remotely access hard to reach and hardly reached populations as well."

We are proud to share that we’ve been selected to be part of the JVP & Margalit Startup City Haifa - Digital Health Innovation program. It's an honor to be part of a group of companies developing cutting-edge digitalhealth technologies in order to save lives.

At the e-Health Investment Forum on June 15th, great companies will do their pitches LIVE on stage! Discover more about Cardiokol, Virtuleap, Braingaze and nen in the category growth live at the EHIF event.

Six Israeli startups presented to a panel of top global industry analysts and influencers as part of the final event, with Cardiokol winning the most innovative solution, and UpNext GenZ's pitch being named as most creative.

Other finalists included: FutureEcom, Outgage and Ovo Automotive

Our G4A alumni company Cardiokol’s pitch has won the most innovative solution at Oracle Startup Idol Israel among six startups. Cardiokol is a #telehealth company that commercializes voice-based markers and technologies for enhanced identification and monitoring of common heart rhythm abnormalities in large populations at risk. Do you want to partner with Cardiokol? On June 23, you can join our G4A virtual DigitalHealthForum to meet Cardiokol among 20 of G4A's most promising alumni firms.

We won Most Innovative Solution Oracle startup
Idol – Israeli edition!

Thank you to the industry analysts and influencers who voted for us. And thank you to the five other super impressive startups and founders who participated.

On June 23, Bayer G4A will host the virtual #DigitalHealthForum and we are honored to be recognized as one of the most promising Bayer G4A alumni companies attending the G4A Alumni Expo.On May 17, we’ll pitch to industry analysts against five other super impressive startups for prizes of Most Creative, Most Innovative, and Best Overall. Stay tuned to see if we win.

We’ve been selected for Oracle Startup Idol – Israel edition!Title copy goes here

On May 17, we’ll pitch to industry analysts against five other super impressive startups for prizes of Most Creative, Most Innovative, and Best Overall. Stay tuned to see if we win.

Great welcome to our new team members: Alon Liberman and Gabriel Zackon, Algorithm Developers.

Great welcome to our new team members: madlin abbas, CRA and Inbar Zolkov, Algorithm Engineer & Project Manager.

Together we will further develop the ability to use voice in order to save lives!

Cardiokol Using Voice to Save Lives

During the pitch organized for the companies participating in H+ Digital Health Innovation Program, run by InsurTech Hub Munich, our CEO James Amihood presented some key estimated cost saving for #insurers, when using advanced technology solutions for detecting suspected AF.On May 17, we’ll pitch to industry analysts against five other super impressive startups for prizes of Most Creative, Most Innovative, and Best Overall. Stay tuned to see if we win.

"The estimated cost saving for the insurers in Germany is more than 1.5 billion euros a year”.

Please watch the 3 min. video to learn more about the unique value proposition of Cardiokol for insurers.

We're happy to inform you that Cardiokol was selected by the Israel Innovation Authority to exhibit in Biomed Israel 2022 Startup Pavilion on May 12th
(booth 31).

Biomed Israel conference is the leading event of Israel’s life sciences industry, and well positioned both in Israel and the international market.The conference brings together thousands of international visitors and reflects the most innovative solutions in the industry.In the pavilion you will be able to learn about the commercial product that Cardiokol offers for the detection of Atrial Fibrillation from speech, and future solutions will also be presented.

Insurance & Chronic Diseases:
How can insurers support chronic disease patients?

50% of the German population has a chronic disease. Demographic shifts and longer life expectancy have made chronic diseases a pressing topic, constantly challenging healthcare systems with increasing costs and affecting patients’ quality of life. We have asked Markus Buchhäusl, Head of Digitalization, Technology and Business Organization and Teresa Hoess, Healthcare Manager at ARAG to discuss with us the role of insurers in supporting chronic patients and their views on possible effective solutions.

A shoutout to all our chronic disease startups joining the H+ Digital Health Programme for bringing in personalized and engaging solutions to improve chronic diseases and the rehabilitation journey: Ampersand Health, Cardiokol, KINFINITY Solutions, medicalmotion GmbH, Mia-Care, Perfood, Sensely and TakesCare. Check out their amazing solutions!

A Chat with James Amihood, CEO at Digital Telehealth Company: Cardiokol

Cardiokol CEO James Amihood recently sat down with Dana Leigh at TechRound to talk about the company and how they've developed voice-based markers and methods for monitoring and screening #heartrhythm disorders in large at-risk populations.We asked Yirmi: "What will the future of Cardiokol's VAAM (Voice-Assisted Arrhythmia Monitoring) look like?"

The company’s software applications ongoingly analyse daily voice samples through commonly-used voice-interfaces, to detect and track its proprietary vocal biomarkers of risky, treatable and “silent” health conditions.

Join us on April 6th for InsurTech Hub Munich final HEALTH X INSURANCE SHOWCASE where cutting-edge solutions that support the insurers’ transformation from payor to health care partners will be presented.It has been an intense Innovation Programme and we can’t wait to pitch alongside other ambitious and inspiring startups from the H+ Digital Health Program and hear from healthcare experts like Bart De Witte - Hippo AI Foundation, Ludovic Pureur - Virgin Pulse, Dr. Olivier Flückiger - RoX Health, Peter Stockhammer - Generali Vitality, Francesca Tamma - Swiss Re and many more!

We asked Yirmi: "What will the future of Cardiokol's VAAM (Voice-Assisted Arrhythmia Monitoring) look like?"

Yirmi replied: "By simple voice analysis, experts will be able to:
1. Diagnose & monitor physical status, and provide an initial feedback
2. Track patients' health condition over time

For example, a patient will call an emergency medical center and as part of this initial call a voice app will analyse his/her voice, screen various health parameters and his/her condition and provide the doctor with essential information and recommendations for additional diagnosis. This is a mass screening solution for disease detection targeting large populations. This solution has high accessibility and is very cost-effective. In the future, I believe it will be integrated within personal phone assistants systems as well. It will save precious time for people who already have risk factors. Many companies are developing solutions in this field for various diseases while we at Cardiokol are uniquely focused on Afib to start. I think the main challenge here is the collection of data. It needs to be big and diversified enough in order to make this future forecast a reality.

My professional motto is: Speech contains more secrets than the text"

Recent publication in the European Heart Journal - titled "Targeted vs full population screening costs for incident Atrial Fibrillation and AF-related stroke for a healthy population aged 65 years in the United Kingdom" - has studied how an opportunistic #AF screening program would impact on #healthcare costs of AF (and AF-related stroke) for the NHS.

Study results show that "focusing on 2030 and should opportunistic screenings for AF be introduced at age 65, with subsequent treatment, it is predicted to reduce the number of stroke cases over the decade by 5,888 if all 65 year olds are screened and 695 if just the high risk group are screened. If the number of strokes can be reduced by treating these screened AF patients, we would substantially reduce the health and social care costs of stroke by £654.6m and £77.3m respectively."

Cardiokol's deviceless Voice-Assisted Arrhythmia Monitoring (VAAM) products are aimed at a more cost-effective mass-screening for AF burdens (associated with higher #stroke risk and clinical outcome than short AF episodes) in large, at-risk populations over the age of 65.

We're happy to share with you an interview translated from Hebrew with Dr. Gregory Golovchiner, recently published in Haaretz magazine.

Dr. Golovchiner, Head of the Electrophysiology and Pacing Unit at Rabin Medical Center, carried out research using Cardiokol's proprietary vocal biomarker software, in order to provide early detection of patients with suspected atrial fibrillation.
Dr. Golovchiner has been the company's medical consultant since its inception.

“The online application asks the patients to say ‘ahh’ three times a day, and the developed technology detects if they are having an atrial fibrillation episode. A smart scheduling algorithm that increases the accuracy of detection has also been developed. The technology can be embedded in different systems - from smartphones and landline phones to technology assistants like Siri and Alexa, etc. so that we can keep track of those who are at risk,“ he explains.

We’re honored to be selected out of 270 applicants for the H+ Digital Health Innovation Program (https://lnkd.in/dQbev5s2), run by InsurTech Hub Munich, and join 19 global digital health companies in this unique and prestigious program.

The program was founded by the private insurance companies in Germany, whom are interested in promoting innovation in the digitalhealth area by initiating pilots with the program participants. For Cardiokol, it’s a great opportunity to cooperate with private insurance firms, and provide innovative software to detect new Atrial Fibrillation patients and save their lives.

We at Cardiokol had a very beneficial and fruitful time working with Bayer G4A team during the Growth Accelerator program over the last 10 weeks.

During this period we presented our vision and our unique Atrial Fibrillation vocal biomarker to support the saving of lives.
We look forward to continuing working with the great team at Bayer/G4A and to all the milestones we want to achieve together.

If you are a manager or an entrepreneur of a company in the field of digital health, we strongly encourage you to apply for one of the Bayer programs. This could be the best outcome for you in 2022!!
Thanks also to Brian Drozdowicz, Dominick Kennerson, Sophie P., Bayer G4A team & all external mentors/advisors for being such great hosts during the virtual event!

Reach out if you want to learn more about using voice to save lives.

Recent and notable clinical studies show that Afib monitoring based on twice daily tests (the Strokestop study) detects fewer Afib cases but at higher risk of stroke, while continuous monitoring (the LOOP study, using implantable monitor) detects shorter Afib episodes that are clinically less relevant.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse tincidunt sagittis eros. Quisque quis euismod lorem. Etiam sodales ac felis id interdum.

In other words, daily Afib tests present a more cost-effective monitoring method, with more actionable steps (and clinical outcomes) vs continuous monitoring.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse tincidunt sagittis eros. Quisque quis euismod lorem. Etiam sodales ac felis id interdum.

Cardiokol's first product for daily Afib tests is entirely aligned with these recent findings. Cardiokol's 'VAAM" (Voice Assisted Arrhythmia Monitoring) utilizes daily voice samples to detect the more dangerous and often "silent" Afib burdens, rather than any Afib episode, while using a most cost-effective and age-friendly manner.Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse tincidunt sagittis eros. Quisque quis euismod lorem. Etiam sodales ac felis id interdum.

We have been accepted for the very exciting Bayer G4A partnerships Program for 2021" We are very proud and excited in being selected by Bayer as one of the Finalists of this year's G4A Growth.